In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Provectus Biopharmaceuticals Inc.

www.pvct.com

Latest From Provectus Biopharmaceuticals Inc.

Boehringer Targets Hearing Loss In First China Pharma R&D collaboration

Joining a growing number of its multinational peers tapping into China’s expanding innovative capabilities, Boehringer Ingelheim has teamed up with an academic research group to develop novel stem cell therapies for hearing loss, further encouraged by new state support for regenerative medicine.

China Research and Development Strategies

Deals Shaping the Medical Industry, September 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2016.

Deals BioPharmaceutical

Deals Shaping The Medical Industry, July 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2015.

BioPharmaceutical Medical Device

Amgen’s T-VEC AdCom May Shed Light On How FDA Reviews Intralesional Immunotherapies

FDA’s Oncologic Drugs and Cellular, Tissue and Gene Therapies advisory committees will weigh in on a new molecular entity in a nascent field of cancer vaccines April 29; could set precedent for other intralesional drug reviews.

BioPharmaceutical North America
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Laser
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Alias(es)
  • Provectus Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Provectus Biopharmaceuticals Inc.
  • Senior Management
  • John R Glass, Interim CFO
    Eric Wachter, PhD, CTO
    Timothy Scott, PhD, Pres.
  • Contact Info
  • Provectus Biopharmaceuticals Inc.
    Phone: (866) 594-5999
    7327 Oak Ridge Hwy.
    Knoxville, TN 37931
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register